At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
MGCD516drug
Likely dose
MGCD516 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating MGCD516 for Liposarcoma and Metastatic Liposarcoma. Completed, enrolled 29 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate Sitravatinib, an oral small molecular receptor tyrosine kinase inhibitor, for the treatment of advanced liposarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiposarcoma, Metastatic Liposarcoma
CountriesUnited States
CollaboratorsMirati Therapeutics Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionJan 2020
Study CompletionDec 2021
TodayJul 2026
First PostedDec 1, 2016
Enrollment StartNov 1, 2016
Primary CompletionJan 1, 2020
Study CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.6 years ago
Interventions
MGCD516drug
Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.